Luseogliflozin
目录号: A13476
SGLT2 抑制剂
Luseogliflozin 是由泰松制药开发的一种口服活性的第二代 钠-葡萄糖共转运蛋白2(SGLT2)抑制剂,用于治疗2型糖尿病(T2DM)患者。
| Discription | Luseogliflozin is an orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Taisho Pharmaceutical for the treatment of patients with type 2 diabetes mellitus (T2DM). |
|---|
| 目录号 | A13476 |
|---|---|
| 分子式 | C23H30O6S |
| 分子量 | 434.55 |
| CAS号 | 898537-18-3 |
| SMILES | CCOC1=CC=C(C=C1)CC2=C(C=C(C(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](S3)CO)O)O)O)OC)C |
| 其他名称 | TS 071, TS071, TS-71 |
| 储存条件 | Store lyophilized at -20ºC, keep desiccated. |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2